In February 2022, The U.S. Food and Drug Administration (FDA) accepted adagrasib (A for an>dagrasib) (NDA), for the treatment of previously treated kras Patients with 12c-positive non-small cell lung cancer. In December 2022, the FDA accelerated approval of adagrasiib for the treatment of locally advanced or metastatic non-small cell lung cancer with kras 12c mutations, and these patients have received at least one previous systemic therapy. Adagrasibmarketed as 200mg film-coated tablets, the active ingredient is adagrasib, a KRAS G12C (Kirsten rat sarcoma virus oncogene homolog) inhibitor that covalently and irreversibly binds to the unique cysteine u200bu200bof KRAS G12C.
.jpeg)
